1–3个脑转移且预后良好患者立体定向放疗或手术后全脑放疗:EORTC 22952-26001二次分析
该研究为Ⅲ期随机试验EORTC 22952-26001的二次分析,纳入329例按方案治疗、1–3个脑转移的患者,中位随访26个月。将颅外进展作为时依协变量或在非小细胞肺癌(NSCLC)中按诊断特异性分级预后评估(GPA)评分分层后,全脑放疗(WBRT)均未显示显著生存获益。作者认为该探索性分析支持对接受立体定向放疗(SRS)并密切随访的有限脑转移患者省略WBRT。
要点
- 329例按方案治疗患者中,115例(35%)无颅外进展。
- 颅外进展前后,WBRT组死亡风险均无显著差异(HR 0.70与1.20,95%CI均含1)。
- NSCLC患者中GPA良好与不良者,WBRT均无显著生存获益。
核心结论
- 在入组时颅外病变有限、1–3个脑转移的患者中,NSCLC且GPA评分良好者以及任何组织学类型且颅外病变控制者,WBRT均无显著生存获益。
- 该Ⅲ期数据探索性分析支持对接受SRS并密切随访的有限脑转移患者省略WBRT。
研究设计与样本
- EORTC 22952-26001的二次分析,采用Cox回归、landmark分析和Kaplan-Meier法。
- 纳入329例按方案治疗的患者,中位随访26个月。
主要发现
- 115例(35%)无颅外进展;70例(21%)在<90天进展,65例(20%)在90–180天进展,79例(24%)在>180天进展。
- WBRT组颅外进展前死亡风险HR 0.70(95%CI 0.45–1.11,P=0.133),进展后HR 1.20(95%CI 0.89–1.61,P=0.214),均无显著差异。
- 177例NSCLC患者中175例可计算GPA;GPA良好者HR 1.10(95%CI 0.68–1.79),GPA不良者HR 1.11(95%CI 0.71–1.76),均无显著生存获益。
局限性
- 原文为对Ⅲ期数据的探索性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The absence of a survival benefit for whole brain radiotherapy (WBRT) among randomized trials has been attributed to a competing risk of death from extracranial disease. We re-analyzed EORTC 22952 to assess the impact of WBRT on survival for patients with controlled extracranial disease or favorable prognoses. PATIENTS AND METHODS: We utilized Cox regression, landmark analysis, and the Kaplan-Meier method to evaluate the impact of WBRT on survival accounting for (i) extracranial progression as a time-dependent covariate in all patients and (ii) diagnosis-specific graded prognostic assessment (GPA) score in patients with primary non-small-cell lung cancer (NSCLC). RESULTS: A total of 329 patients treated per-protocol were included for analysis with a median follow up of 26 months. One hundred and fifteen (35%) patients had no extracranial progression; 70 (21%) patients had progression <90 days, 65 (20%) between 90 and 180 days, and 79 (24%) patients >180 days from randomization. There was no difference in the model-based risk of death in the WBRT group before [hazard ratio (HR) (95% CI)=0.70 (0.45-1.11), P = 0.133), or after [HR (95% CI)=1.20 (0.89-1.61), P = 0.214] extracranial progression. Among 177 patients with NSCLC, 175 had data available for GPA calculation. There was no significant survival benefit to WBRT among NSCLC patients with favorable GPA scores [HR (95% CI)=1.10 (0.68-1.79)] or unfavorable GPA scores [HR (95% CI)=1.11 (0.71-1.76)]. CONCLUSIONS: Among patients with limited extracranial disease and one to three brain metastases at enrollment, we found no significant survival benefit to WBRT among NSCLC patients with favorable GPA scores or patients with any histology and controlled extracranial disease status. This exploratory analysis of phase III data supports the practice of omitting WBRT for patients with limited brain metastases undergoing SRS and close surveillance. CLINICAL TRIALS NUMBER: NCT00002899.
引用
- Churilla TM, Handorf E, Collette S, et al. Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001. Ann Oncol. 2017. PMID: 28961826. doi:10.1093/annonc/mdx332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。